Feature | July 25, 2013

First Robotic-Assisted STEMI Stent Performed at Sanford Aberdeen Medical Center

Interventional cardiologist performs CorPath Robotic angioplasty, door-to-balloon time superior to national average

CorPath Robotic Angioplasty Corindus Sanford Aberdeen Medical Center South Dakot

July 25, 2013 — Sanford Aberdeen Medical Center in Aberdeen, S.D. became the first hospital to perform a robotic angioplasty for a patient with an acute heart attack, achieving a far better door-to-balloon time than the national standard. Interventional cardiologist Puneet Sharma, performed the percutaneous coronary intervention (PCI) to treat a patient that had experienced a heart attack and presented to the Sanford Aberdeen emergency department. Utilizing the U.S. Food and Drug Administration (FDA)-cleared CorPath System, Sharma was able to perform the robotic-assisted angioplasty procedure and restore blood flow to the patient’s heart within 68 minutes of their arrival.

The current nationwide standard for door-to-balloon time — from when a patient with a heart attack is presented to the emergency department (ED) to inflating a balloon in his coronary arteries to restore blood flow to the heart — is 90 minutes. These standards were developed by the American College of Cardiology (ACC) to improve timely access to the cath lab and by that improving clinical outcome.

“Timely access to emergency cardiac care and survival is partly dependent on access to services and technology,” said Sharma. “Being able to perform a CorPath Robotic Angioplasty on a STEMI patient within 68 minutes is a great benefit. As shown with the latest procedure, robotic-assisted angioplasties improve rural access and quality of care as more patients in this area will have access for advanced specialty care. The implementation of the CorPath System and its ability to precisely and rapidly execute an angioplasty procedure with only one stent in the patient heart is a great example of Sanford Health’s commitment to enhanced clinical outcome for our patients.”

The CorPath System is the first and only FDA cleared technology that enables precise, robotic-assisted angioplasties to open arteries and restore blood flow in patients with coronary artery disease. Seated in an interventional cockpit, the interventional cardiologist advances stents and guidewires via a joystick with millimeter-by-millimeter precision. The system, which is quickly being adopted as the new standard of care in coronary angioplasty procedures, may also improve clinical outcomes by enabling precise measurement of the anatomy, which could potentially lead to better stent placements.

Sanford Health performs robotic-assisted angioplasty procedures with the CorPath System at both Sanford Heart Hospital in Sioux Falls and Sanford Aberdeen Medical Center. It is the first and only health system in the region utilizing the CorPath System.

For more information: www.corindus.com

Related Content

FDA, CDRH, national evaluation system, medical device development
Feature | Business| May 04, 2016
The U.S. Food and Drug Administration (FDA) announced it is building the foundations of a national evaluation system to...
radiation dose in the cath lab
News | Radiation Dose Management| May 02, 2016
May 2, 2016 — Starting at the Society for Cardiovascular Angiography and Interventions (SCAI) 2016 annual meeting May
Feature | Business| April 28, 2016 | Dave Fornell
 
Technology | Stents Peripheral| April 27, 2016
Veniti Inc. announced the first successful treatment with the Vici Verto Venous Stent System of a patient suffering...
Auris Surgical Robotics, acquisition, Hansen Medical
News | Robotic Systems| April 26, 2016
Auris Surgical Robotics Inc. and Hansen Medical Inc. announced that they have signed a definitive merger agreement...
Siemens Sensis Vibe, hemodyanamics system

Siemens released the Sensis Vibe hemodyanamics system at ACC.16. The newer system offers better integration of cath lab data into cath lab reports and the electronic medical record (EMR).

Feature | ACC| April 25, 2016 | Jon Brubaker, MBA, RCVT, Tom Watson, BS, RCVT, and Sabrina Newell MS, RCS
There were several trends seen in new cardiovascular technologies showcased on the expo floor at the 2016 American...
Medtronic, Drug-Filled Stent, RevElution Trial results, ACC.16, CE Mark
News | Stents Drug Eluting| April 21, 2016
Medtronic plc announced new clinical data from one of the endpoints in the RevElution Trial for its novel, next-...
Boston Scientific, Fetch 2 aspiration catheter, Class 1 recall
News | Thrombectomy Devices| April 20, 2016
April 20, 2016 — Boston Scientific Corp. announced a U.S.
ischemic postconditioning, STEMI patients, clinical outcomes, ACC.16
News | Cath Lab| April 19, 2016
A large randomized controlled trial of ischemic postconditioning in patients who had experienced ST-segment elevation...
STEMI, delayed or deferred stent implantation, DANAMI-3-DEFER trial, ACC.16
News | Cath Lab| April 18, 2016
Delayed or deferred stent implantation in patients showed no clinical benefit in patients experiencing the deadliest...
Overlay Init